Skip to content
Screener

Tango Therapeutics TNGX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$22.61M-7.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$28.27M-10.3%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$17.55M-10.5%
Immunome logo
ImmunomeIMNM
$2.83M-32.1%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$2.49M-34.9%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$5.04M-15.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemMarch 31, 2026December 31, 2025
Prepaid expenses and other current assets12,48810,190
Total current assets392,327353,756
Property and equipment, net6,3816,868
Operating lease right-of-use assets34,65235,624
Restricted cash, net of current portion2,1392,139
Other assets293303
Total assets$435,792$398,690
Liabilities and Stockholders' Equity

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's operating lease ROU assets?
Tango Therapeutics (TNGX) reported operating lease ROU assets of $34.65M in Q1 2026.
How has Tango Therapeutics's operating lease ROU assets changed year-over-year?
Tango Therapeutics's operating lease ROU assets decreased by 12.7% year-over-year, from $39.7M to $34.65M.
What is the long-term trend for Tango Therapeutics's operating lease ROU assets?
Over 5 years (2020 to 2025), Tango Therapeutics's operating lease ROU assets has grown at a 36.6% compound annual growth rate (CAGR), from $7.48M to $35.62M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Tango Therapeutics's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude